|
|
Accelerate Diagnostics Inc (NASDAQ: AXDX) |
|
Price: $0.5400
$-0.01 
-1.099%
|
| Day's High:
| $0.6358
| Week Perf:
| -10 %
|
| Day's Low: |
$ 0.50 |
30 Day Perf: |
-50.46 % |
| Volume (M): |
36 |
52 Wk High: |
$ 2.09 |
| Volume (M$): |
$ 20 |
52 Wk Avg: |
$1.32 |
| Open: |
$0.53 |
52 Wk Low: |
$0.49 |
|
|
| Market Capitalization (Millions $) |
13 |
| Shares
Outstanding (Millions) |
23 |
| Employees |
134 |
| Revenues (TTM) (Millions $) |
11 |
| Net Income (TTM) (Millions $) |
-50 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
1 |
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc is a medical technology company that is focused on the development and commercialization of innovative diagnostic solutions. The company's flagship product is the Accelerate Pheno' system, which is designed to provide rapid identification and antibiotic susceptibility testing for infectious diseases. By utilizing advanced molecular and phenotypic technologies, the system aims to help healthcare providers make quicker and more informed treatment decisions. The company is headquartered in Tucson, Arizona and operates globally, serving hospitals and clinical laboratories worldwide.
Company Address: 3950 South Country Club Road Tucson 85714 AZ
Company Phone Number: 365-3100 Stock Exchange / Ticker: NASDAQ AXDX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Accelerate Diagnostics Inc
Accelerate Diagnostics Inc (AXDX) managed to reduce its diminishing returns despite facing a decline in revenues for the financial period ending on June 30, 2024. Revenues decreased by approximately 4.394% to $2.68 million during this period. Furthermore, the shortfall per share depreciated to $-0.50, a significant improvement compared to the $-2.97 EPS reported in the previous year.
These modest financial figures indicate a slight decline in revenue when compared to the previous reporting period, where revenue decreased by approximately 1.726% from $2.72 million. However, there was a positive development in terms of income per share, which improved from $-0.74 per share.
|
| Accelerate Diagnostics Inc
Accelerate Diagnostics Inc. recently released its financial results for the interval closing on March 31, 2024. The report highlights a noticeable decline in revenue, causing a deficit in the company's financial performance. This article aims to outline the key facts and interpret the implications of these results.
1. Decreased Revenue:
In the latest reporting period, Accelerate Diagnostics Inc. experienced a decline in revenue by -3.165%, amounting to $2.72 million. This decrease in revenue demonstrates a challenging business environment. In contrast to the previous year, a drop from $3.03 million, revenue deteriorated by -10.043%.
|
| Accelerate Diagnostics Inc
Accelerate Diagnostics Inc, a company specializing in Laboratory Analytical Instruments, recently reported its financial fourth quarter results for 2023. The company experienced a significant increase in loss per share compared to the same period the year before, with a loss of $-1.86 per share in 2023 compared to $-0.12 in the prior year. Additionally, EPS fell from $0.06 per share in the previous reporting period.
Despite the increase in loss per share, Accelerate Diagnostics Inc saw a slight growth in revenue, with a 1.816% increase to $3.03 million in the fourth quarter of 2023 from $2.97 million in the same period the year before. Sequentially, revenue doubled by 173.442% from $1.11 million.
|
| Accelerate Diagnostics Inc
Accelerate Diagnostics Inc, a leading Laboratory Analytical Instruments company, has seen its stock experience a notable increase over the past seven days, contributing to a remarkable year-to-date performance. Despite facing a decline in revenue and the challenging impact of the pandemic, the company has managed to turn a profit in the July to September 30, 2023 period. This article will examine the financial results and discuss how they may impact the company in the future.
Positive Turnaround:
During the July to September 30, 2023 period, Accelerate Diagnostics Inc achieved a significant milestone by recording an income per share of $0.06. This marks a substantial improvement compared to the previous year when the company reported a loss of $0.18 per share. Moreover, the earnings per share have turned positive from a significant loss of $-2.97 per share in the previous reporting season. This positive financial turnaround is certainly a promising sign for Accelerate Diagnostics Inc.
|
| Accelerate Diagnostics Inc
Accelerate Diagnostics Inc (AXDX) has reported an increase in losses for the fiscal time-frame ending June 30, 2023, primarily due to weak demand. The net loss per share advanced to $-2.97 from $-0.24, indicating a significant decline in profitability. Additionally, the company's revenue witnessed a decline of 27.506%, amounting to $2.80 million compared to $3.86 million in the previous year.
In comparison to the previous quarter, there was a slight decrease in revenue by 0.462%, from $2.81 million. Furthermore, there was a surge in loss per share from $-0.17. These figures highlight the ongoing struggles faced by Accelerate Diagnostics Inc in maintaining a stable financial performance.
For the financial time-frame ending June 30, 2023, Accelerate Diagnostics Inc recorded a net loss of $-32.735 million, surpassing the loss of $-18.523 million reported a year ago. This reflects a continuing trend of declining profitability for the company.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.09 $ |
| Revenues (TTM) |
0.46 $
|
| Cash Flow (TTM) |
0.13 $ |
| Cash |
0.7 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.09 $
|
| Revenues (TTM) |
0.46 $ |
| Cash Flow (TTM) |
0.13 $ |
| Cash |
0.7 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| Domestic |
|
 95.24 % |
of total Revenue |
| Foreign |
|
8.93 % |
of total Revenue |
| Products |
|
91.7 % |
of total Revenue |
| Services |
|
12.46 % |
of total Revenue |
|
|
